LEGN250117C37500
- 1.20
- -0.10-7.69%
Legend Biotech Newsroom
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $65 to $91
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Optimistic Buy Rating for Legend Biotech Driven by Carvykti's Success and Growth Potential
William Blair Sticks to Its Hold Rating for Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $86
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $83
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
Analysts Conflicted on These Healthcare Names: NeueHealth Inc (NEUE), Agilent (A) and Legend Biotech (LEGN)
Legend Biotech (LEGN) Gets a Buy From RBC Capital
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $82
Morgan Stanley Remains a Buy on Legend Biotech (LEGN)
Truist Financial Maintains Legend Biotech(LEGN.US) With Buy Rating
Legend Biotech (LEGN) Gets a Buy From Truist Financial
Cantor Fitzgerald Maintains Legend Biotech(LEGN.US) With Buy Rating, Raises Target Price to $83
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $76
Legend Biotech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $73 to $94